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SUMMARY - Cluster headache is an extremely painful syndrome that occurs more frequently
in men. Although periodic in most cases, cluster headache has a considerable impact on the patient
quality of life. Acute therapy is usually not sufficient and most patients warrant prophylactic tre -
atment. The aim of this study was to evaluate the efficacy and safety of gabapentin as prophylaxis
in patients with cluster headache previously successfully or unsuccessfully treated with other prop-
hylactic medications. The study included 14 patients, 9 men and 5 women (mean age 42±15 years).
Gabapentin was gradually introduced; the maintenance dose was in the range from 900 mg to 2400
mg: 900 mg/day in 6, 1200 mg/day in 2, 1800 mg/day in 4 and2400 mg/day in 2 patients. The mean
duration of treatment was 3.5 (range 2-5) months. Within 1-2 weeks, patients reported response to
treatment. The mean number ofheadache days/4 weeks was reduced from 378 (mean 27) at baseline
to 210 (mean 15) at the end offollow up, yielding a reduction by 12 headache days/4 weeks or by
44.94% in headache frequency. Pain intensity was decreased by 25% in 1 (7.14%) patient, by 50%
in 8 (57.14%) and by 75% in 3 (21.4%) patients, whereas 2 (14.28%) patients were non-responders.
Upon completion ofgabapentin therapy, there were no recurrent in treated patients. Adverse events
were reported in 8/14 (57.14%) patients and were generally of mild to moderate severity. The most
frequently reported adverse events were drowsiness, dizziness, slowness and constipation. There
were no drop-outs due to adverse events.
Key words: Cluster headache - drug therapy; Cluster headache - prevention and control,'Acetic acid -
therapeutic use;Analgesic - therapeutic use;Migraine - drug therapy
Introduction
Cluster headache is an extremely painful syn-
drome that occurs more frequently in men; the esti-
mated prevalence is less than lW. Although periodic
in most cases, cluster headache has a considerable
impact on the patient quality of life". Most patients
with cluster headache warrant prophylactic treatment,
which usually includes corticosteroids, verapamil and
lithium.'>. Recently, antiepileptic drugs (AEDs) have
also been proposed in prophylaxis, however, there is a
Correspondence to: Vlasta Vukovic, MD, PhD, University De-
partment of Neurology Sestre milosrdnice University Hospital,
Vinogradska c. 29, HR-l0000 Zagreb, Croatia
E-mail: vlasta.vukovicei'uclmail.net
general lack of such studies:". The aim of this study
was to evaluate the efficacy and safety of gabapentin
as prophylaxis in patients with cluster headache previ-
ously successfully or unsuccessfully treated with other
prophylactic medications.
Patients and Methods
It was an open prospective study that included
patients with episodic cluster headache attending
the Headache Clinic at our University Department
of Neurology. Cluster headache was defined accord-
ing to the ICHD-2 criteria'. Patients were included
if they had suffered at least three episodic cluster pe-
riods in previous years, if previous prophylactic treat-
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ment with other medications had failed or had to be
discontinued due to adverse events (previous prophy-
lactic treatment mostly included corticosteroids and/
or verapamil); patients agreed to take no concurrent
prophylactic treatment for headaches (pharmacologi-
calor non-pharmacological); patients had no serious
concomitant diseases and were willing to be available
for follow up for at least 3 months. All patients gave
their informed consent.
Gabapentin was started with one 300 mg capsule
and increased by 300 mg daily up to 900 mg daily;
further increase was made if necessary up to the maxi-
mum dose of 2400 mg. A stepwise increase of medi-
cation was made according to the presence of adverse
events. Upon introducing gabapentin in the treatment,
patients were instructed to keep a diary and note all
days with headache, decrease in headache intensity if
present, increase of gabapentin dosage, acute medica-
tions taken for cluster attacks, and occurrence of ad-
verse events. The patients were told to use their usual
therapy for acute attacks, which included non-steroid
anti-rheumatics and triptans.
The primary efficacy endpoint was the change from
baseline in the mean monthly (28 days) number ofdays
with cluster attacks, decrease of headache intensity
and reduction of the mean number ofacute medication
use. The change in headache intensity was recorded as
a percentage (no change, and decrease by 25%, 50%,
75% or 100%). Assessment of safety and tolerability
included physical, neurologic and laboratory examina-
tions, and spontaneous reports of adverse events.
On statistical analysis, Wilcoxon's signed rank test
was used to compare baseline and end-point values.
had experienced in previous cluster periods, which was
in our patients from 1 to 3 months, followed by one
month in which the dose was gradually tapered off.
The mean duration of treatment was 3.5 (range 2-5)
months. Within 1-2 weeks, patients reported response
to treatment. The mean number of headache days/4
weeks was reduced from 378 (mean 27) at baseline to
210 (mean 15) at the end of follow-up, i.e. a reduc-
tion by 12 headache days/4 weeks, yielding a 44.94%
reduction in headache frequency. Pain intensity was
decreased by 25% in 1 (7.14%) patient, by 50% in 8
(57.14%) and by 75% in 3 (21.4%) patients, whereas
2 (14.28%) patients were non-responders. Upon com-
pletion ofgabapentin therapy, no recurrent attacks oc-
curred in the treated patients. All study patients were
followed-up for at least 3 months (mean follow up, 6
months). The range ofgabapentin doses and reduction
of pain intensity are shown in Table 1.
Before starting the treatment with gabapentin, pa-
tients were taking at least one medication (analgesics
or triptans) daily to treat their attacks. The exact num-
ber of medications previously used for cluster attacks
was not available; however, based on patient recall, a
reduction of acute medication use by at least 50% was
reported in 11 patients, whereas one patient had no
need for acute medication anymore.
Adverse events were reported in 8/14 (57.14%)
patients and were generally of mild or moderate se-
verity. The most frequently reported adverse events
were drowsiness 5/14 (35.7%), dizziness 3/14 (21.4%),
slowness 1/14 (7.1%) and constipation 1/14 (7.1%).









2 (14.28) 4 (28.57)
Gabapentin dosage (mg)
1200 1800
Reduction of pain intensity by %
0%
900
In general, there is a lack of multicenter random-
ized double-blind trials of antiepileptic drugs (AEDs),
2 (14.28)
6 (31.57)
Table 1. (A) Range ofgabapentin doses in patients with clusterheadache;
and (B) reduction ofheadache intensity
B)
Results
The study included 14 patients, 9 men and 5 wom-
en (mean age 42±15 years). The mainte-
nance dose of gabapentin in all patients
was in the range from 900 mg to 2400
mg: 900 mg/day in 6, 1200 mg/day in 2,
1800 mg/day in 4 and 2400 mg/day in A)
2 patients. The dose of gabapentin was ~-----:c:c::----c-::'=-=----~c:c:=---=-c:c::---
not increased over 2400 mg because an
improvement was achieved or adverse
events occurred at this dosage.
Patients were receiving gabapentin
according to the duration of attacks they _N_~_1_4_(,--%-,-)__,----_,---__,------,-__---,__,----_---,-_-,--__
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especially gabapentin, as a prophylactic treatment in
patients with cluster headache. The reasons for this
paucity ofevidence based data are the low prevalence of
cluster headache; cluster periods are usually relatively
short and show a tendency of spontaneous remission,
which may bias study results. Although double-blind
placebo-controlled studies provide unbiased results,
they are sometimes difficult to carry out; therefore,
open-label studies offer additional data on the efficacy
ofpharmacological or non-pharmacological treatment.
Placebo controlled studies in cluster patients would be
unethical due to extremely troublesome symptoms
which patients experience and because other medica-
tions have already been proven in trials to be efficient
in the treatment of cluster headache".
Results of our study showed gabapentin to be ef-
fective as prophylactic treatment of cluster headache
in patients refractory to previous prophylactic therapy.
We observed a significant reduction in headache fre-
quency, intensity and medication use during the fol-
low up period. The high efficacy rates observed in our
study might be promising, since not many prophylac-
tic medications are available for the treatment of this
debilitating condition. We compared our results with
other trials that evaluated the efficacy ofgabapentin in
cluster prophylaxis.
In a case report of episodic cluster headache, gaba-
pentin 300 mg twice daily proved efficient, with a
transient side effect (drowsiness)? Another case re-
port of chronic cluster headache describes response
to gabapentin at a dose of 1800 mg, with the patient
being symptom-frees In an open-label study, 8 epi-
sodic and 4 chronic cluster patients previously refrac-
tory to other prophylactic therapy were treated with
gabapentin 300 mg three times daily; all patients were
pain-free within 8 days of treatment introduction". In
patients with episodic cluster headache, therapy was
discontinued after 2 months and no relapse occurred
during 3 months of follow up; in chronic cluster pa-
tients no new attacks were reported during 4-month
follow up; only two patients reported mild drowsiness
as an adverse event". Gabapentin was also found to be
efficient in patients with chronic cluster headache; 6 of
8 patients refractory to first-line treatment responded
to this therapy".
In three open-label trials, divalproex sodium and
sodium valproate were found to be efficient in reduc-
tion ofheadache frequency; in one trial, 9 of15 patients
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reported complete remission of cluster headaches":':'.
However, a double-blind placebo-controlled study in
96 patients turned out to be unfavorable: a reduction
by at least 50% in the mean number of attacks per
week was observed in the sodium valproate group and
by as much as 62% in the placebo group!'.
In six open label studies with small series of pa-
tients, topiramate was efficient in reducing the fre-
quency of attacks and high percentage of remission
was reported in most of these studies; the response
occurred within 1-3 weeks". Topiramate, 25-100 mg
in 1-2 divided doses during the cluster period and 2
weeks thereafter, reduced cluster attacks in 19 of 27
patients within 3-14 days".
In our study, a significant reduction was recorded
in the number of days with headache and headache
intensity, i.e. by 12 headache days/4 weeks or 44.94%
reduction in headache frequency; our results are simi-
lar to a study with gabapentin9, and to studies with
divalproex sodium-s" and topiramate".
The shortcomings ofour study were the small num-
ber of patients included and study design, as it was not
a placebo-controlled double-blind study. However, it
is unlikely that the results were due to placebo effect,
since prior trials of preventive medications had failed
in most ofour patients. In our study, gabapentin treat-
ment of patients with cluster headache at daily doses of
900-2400 mg resulted in a significant mean reduction
of migraine days, reduction in pain intensity and in
the use ofacute medications. Although adverse events
occurred in a relatively high percentage, the treatment
with gabapentin was safe and well tolerated in the ma-
jority of patients. Our findings warrant further trials,
in a larger number of patients, preferably as double-
blind placebo-controlled studies. However, we hope
that the results of our study will help other clinicians
in the treatment of cluster patients unresponsive to
usual prophylactic treatment.
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Saietak
GABAPENTIN U PROFILAKSI KLUSTER GLAVOBOLJE: OPSERVACIJSKA OTVORENA STUDIJA
V Vukovii, A. Lourenci/-Huxjan, M. Budifiii V Demarin
Kluster glavobolja [e izrazito bolni sindrom koji se ceSce javlja kod muskaraca. Premda se u vecini slucajeva javlja pe-
nodi/no, kluster glavoboja ima znacajan utjecaj na kvalitetu zrvota bolesnika. Akutna terapija najceSce nije dovoljna te je
vecini bolesnika potrebna i profilakucna terapija. Cilj ove studije bio je procijeniti ucinkovitost i sigurnost gabapentina u
profilaksi kluster glavobolje kod bolesnika koji su prethodno uspjesno iii neuspjesno lijeceni drugim profilakttcnrm lije-
kovima. Studija je ukljucivala 14 bolesnika, 9 muskaraca i 5 zena (prosjecne dobi 42±15 godina). Gabapentin se postupno
uvodio u terapiju; doza odrzavanja je bila od 900-2400 mg: 900 mg u 6, 1200 mg u 2, 1800 mg u 4 i 2400 mg na dan u 2
bolesnika. Prosjecno trajanje lqecenja [e bilo 3,5 mjeseci (raspon 2-5 mjeseci). Unutar 1-2 tjedna bolesnici su naveli pobolj-
sanje uz terapiju. Prosjecni broj dana s glavoboljom/4 tjedna bio je smanjcn s 378 (srednja vrijednost 27) na pocetku terapije
na 210 (srednja vrijednost 15) na kraju razdoblja pracenja. sto je smanjenje za 12 dana s glavoboljom /4 tjedna (44,94%).
Intenzitet boli bio je smanjen za 25% kod 1 (7,14%) bolesnika, za 50% kod 8 (57,14%), za 75% kod 3 (21,4%) bolesnika, a 2
(14,28%) bolesnika uopce nisu naveli poboljsanje. Nuspojave je prijavilo 8/14 (57,14%) bolesnika i uglavnom su bile blagog
iii umjerenog intenziteta. NajceSce pnjavljene nuspojave bile su pospanost, omaglica, usporenost i konsupacija. Niti jedan
bolesnik nije prekinuo studiju zbog nuspojava.
Kljucne rijeci: Kluster glavobo!fa - terapiJa liJekovima; Kluster glavobo!fa - prevenciJa i kontrola; Gctena kiselina - terapiJska
primjena; Analgetik - terapiJskaprimjena; Migrena - terapiJa liJekovima
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